Additional sex combs-like family genes are required for normal cardiovascular development

Genesis

Volumn 52, Issue 7, 2014, Pages 671-686

  Mcginley, Andrea L ^a   Li, Yanyang ^a   Deliu, Zane ^a   Wang, Q Tian ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Asx1; Asxl2; Congenital heart disease; Patent ductus arteriosus

Indexed keywords

ASXL1 PROTEIN, MOUSE; ASXL2 PROTEIN, MOUSE; REPRESSOR PROTEIN;

ANIMAL; C57BL MOUSE; EMBRYOLOGY; GENETICS; HEART; MOUSE; MULTIPLE MALFORMATION SYNDROME; PATENT DUCTUS ARTERIOSUS;

ABNORMALITIES, MULTIPLE; ANIMALS; DUCTUS ARTERIOSUS, PATENT; HEART; MICE; MICE, INBRED C57BL; REPRESSOR PROTEINS;

EID: 84904392963     PISSN: 1526954X     EISSN: 1526968X     Source Type: Journal    
DOI: 10.1002/dvg.22793     Document Type: Article

References (84)

1. Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH, Pandey S, Patel JP, Chung YR, Koche R, Perna F, Zhao X, Taylor JE, Park CY, Carroll M, Melnick A, Nimer SD, Jaffe JD, Aifantis I, Bernstein BE, Levine RL. 2012. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22:180-193.
2. Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung YR, Kuscu C, Hricik T, Ndiaye-Lobry D, LaFave LM, Koche R, Shih AH, Guryanova OA, Kim E, Li S, Pandey S, Shin JY, Telis L, Liu J, Bhatt PK, Monette S, Zhao X, Mason CE, Park CY, Bernstein BE, Aifantis I, Levine RL. 2013. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med 210: 2641-2659.
3. Bainbridge MN, Hu H, Muzny DM, Musante L, Lupski JR, Graham BH, Chen W, Gripp KW, Jenny K, Wienker TF, Yang Y, Sutton VR, Gibbs RA, Ropers HH. 2013. De novo truncating mutations in ASXL3 are associated with a novel clinical phenotype with similarities to Bohring-Opitz syndrome. Genome Med 5:11.
4. Baker K, Sanchez-de-Toledo J, Munoz R, Orr R, Kiray S, Shiderly D, Clemens M, Wearden P, Morell VO, Chrysostomou C. 2012. Critical congenital heart disease-Utility of routine screening for chromosomal and other extracardiac malformations. Congenit Heart Dis 7:145-150.
5. Baragatti B, Brizzi F, Ackerley C, Barogi S, Ballou LR, Coceani F. 2003. Cyclooxygenase-1 and cyclooxygenase-2 in the mouse ductus arteriosus: individual activity and functional coupling with nitric oxide synthase. Br J Pharmacol 139:1505-1515.
6. Baskind H, Na L, Ma Q, Patel MP, Geenen DL, Wang QT. 2009. Functional conservation of Asxl2, a murine homolog for the Drosophila enhancer of trithorax and polycomb group gene Asx. PLoS One 4:e4750.
7. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL. 2011. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:2946-2506.
8. Bruneau BG, Nemer G, Schmitt JP, Charron F, Robitaille L, Caron S, Conner DA, Gessler M, Nemer M, Seidman CE, Seidman JG. 2001. A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. Cell 106:709-721.
9. Burn J, Brennan P, Little J, Holloway S, Coffey R, Somerville J, Dennis NR, Allan L, Arnold R, Deanfield JE, Godman M, Houston A, Keeton B, Oakley C, Scott O, Silove E, Wilkinson J, Pembrey M, Hunter AS. 1998. Recurrence risks in offspring of adults with major heart defects: results from first cohort of British collaborative study. Lancet 351:311-316.
10. Chang H-Y, Locker J, Lu R, Schuster VL. 2010. Failure of postnatal ductus arteriosus closure in prostaglandin transporter-deficient mice. Circulation 121:529-536.
11. Chang C-P, Bruneau BG. 2012. Epigenetics and cardiovascular development. Annu Rev Physiol 74:41-68.
12. Delgado-Olguín P, Huang Y, Li X, Christodoulou D, Seidman CE, Seidman JG, Tarakhovsky A, Bruneau BG. 2012. Epigenetic repression of cardiac progenitor gene expression by Ezh2 is required for postnatal cardiac homeostasis. Nat Genet 44:343-347.
13. Dey A, Seshasayee D, Noubade R, French DM, Liu J, Chaurushiya MS, Kirkpatrick DS, Pham VC, Lill JR, Bakalarski CE, Wu J, Phu L, Katavolos P, LaFave LM, Abdel-Wahab O, Modrusan Z, Seshagiri S, Dong K, Lin Z, Balazs M, Suriben R, Newton K, Hymowitz S, Garcia-Manero G, Martin F, Levine RL, Dixit VM. 2012. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science 337:1541-1546.
14. Dinwiddie DL, Soden SE, Saunders CJ, Miller NA, Farrow EG, Smith LD, Kingsmore SF. 2013. De novo frameshift mutation in ASXL3 in a patient with global developmental delay, microcephaly, and craniofacial anomalies. BMC Med Genomics 6:32.
15. Drayton MR, Skidmore R. 1987. Ductus arteriosus blood flow during first 48 hours of life. Arch Dis Child 62:1030-1034.
16. Echtler K, Stark K, Lorenz M, Kerstan S, Walch A, Jennen L, Rudelius M, Seidl S, Kremmer E, Emambokus NR, von Bruehl ML, Frampton J, Isermann B, Genzel-Boroviczény O, Schreiber C, Mehilli J, Kastrati A, Schwaiger M, Shivdasani RA, Massberg S. 2010. Platelets contribute to postnatal occlusion of the ductus arteriosus. Nat Med 16:75-82.
17. Fisher C, Berger J, Randazzo F, Brock HW. 2003. A human homolog of Additional sex combs, ADDITIONAL SEX COMBS-LIKE 1, maps to chromosome 20q11. Gene 306:115-126.
18. Fisher C, Lee I, Bloyer S, Bozza S, Chevalier J, Dahl A, Bodner C, Helgason CD, Hess JL, Humphries RK, Brock HW. 2010a. Additional sex combs-like 1 belongs to the enhancer of trithorax and polycomb group and genetically interacts with Cbx2 in mice. Dev Biol 337:9-15.
19. Fisher CL, Pineault N, Brookes C, Helgason CD, Ohta H, Bodner C, Hess JL, Humphries RK, Brock HW. 2010b. Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 115:38-46.
20. Frey N, Olson EN. 2003. Cardiac hypertrophy: The good, the bad, and the ugly. Annu Rev Physiol 65:45-79.
21. Gelsi-Boyer V, Trouplin V, Adélaïde J, Bonansea J, Cervera N, Carbuccia N, Lagarde A, Prebet T, Nezri M, Sainty D, Olschwang S, Xerri L, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D. 2009. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 145:788-800.
22. Gill HK, Splitt M, Sharland GK, Simpson JM. 2003. Patterns of recurrence of congenital heart disease. J Am Coll Cardiol 42:923-929.
23. Gitler AD, Lu MM, Jiang YQ, Epstein JA, Gruber PJ. 2003. Molecular markers of cardiac endocardial cushion development. Dev Dyn 228:643-650.
24. Goldberg AD, Allis CD, Bernstein E. 2007. Epigenetics: A landscape takes shape. Cell 128:635-638.
25. Granados-Riveron J, Pope M, Bu'lock FA, Thornborough C, Eason J, Setchfield K, Ketley A, Kirk EP, Fatkin D, Feneley MP, Harvey RP, Brook JD. 2012. Combined Mutation Screening of NKX2.5, GATA4, and TBX5 in Congenital Heart Disease: Multiple heterozygosity and novel mutations. Congenit Heart Dis 7:151-159.
26. Hamilton BA, Yu BD. 2012. Modifier genes and the plasticity of genetic networks in mice. PLoS Genet 8:e1002644.
27. Hastings R, Cobben J-M, Gillessen-Kaesbach G, Goodship J, Hove H, Kjaergaard S, Kemp H, Kingston H, Lunt P, Mansour S, McGowan R, Metcalfe K, Murdoch-Davis C, Ray M, Rio M, Smithson S, Tolmie J, Turnpenny P, van Bon B, Wieczorek D, Newbury-Ecob R. 2011. Bohring-Opitz (Oberklaid-Danks) syndrome: Clinical study, review of the literature, and discussion of possible pathogenesis. Eur J Hum Genet 19:513-519.
28. Hatcher CJ, Diman NY, McDermott DA, Basson CT. 2003. Transcription factor cascades in congenital heart malformation. Trends Mol Med 9:512-515.
29. He A, Ma Q, Cao J, von Gise A, Zhou P, Xie H, Zhang B, Hsing M, Christodoulou DC, Cahan P, Daley GQ, Kong SW, Orkin SH, Seidman CE, Seidman JG, Pu WT. 2012. Polycomb repressive complex 2 regulates normal development of the mouse heart. Circ Res 110:406-415.
30. Hoischen A, van Bon BWM, Rodríguez-Santiago B, Gilissen C, Vissers LELM, de Vries P, Janssen I, van Lier B, Hastings R, Smithson SF, Newbury-Ecob R, Kjaergaard S, Goodship J, McGowan R, Bartholdi D, Rauch A, Peippo M, Cobben JM, Wieczorek D, Gillessen-Kaesbach G, Veltman JA, Brunner HG, de Vries BB. 2011. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. Nat Genet 43:729-731.
31. Hsu Y, Osinski J, Campbell C. 2011. Mesenchymal nuclear factor IB regulates cell proliferation and epithelial differentiation during lung maturation. Dev Biol 354:242-252.
32. Huang J, Cheng L, Li J, Chen M, Zhou D, Lu MM, Proweller A, Epstein JA, Parmacek MS. 2008. Myocardin regulates expression of contractile genes in smooth muscle cells and is required for closure of the ductus arteriosus in mice. J Clin Invest 118:515-525.
33. Huntington K, Hunter AG, Chan KL. 1997. A prospective study to assess the frequency of familial clustering of congenital bicuspid aortic valve. J Am Coll Cardiol 30:1809-1812.
34. Ieda M, Tsuchihashi T, Ivey KN, Ross RS, Hong T-T, Shaw RM, Srivastava D. 2009. Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling. Dev Cell 16:233-244.
35. Iourov IY, Vorsanova SG, Kurinnaia OS, Yurov YB. 2013. An interstitial 20q11.21 microdeletion causing mild intellectual disability and facial dysmorphisms. Case Rep Genet 2013:9-13.
36. Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, Visconte V, Sugimoto Y, Prince C, O'Keefe C, Hsi ED, List A, Sekeres MA, Rao A, McDevitt MA, Maciejewski JP. 2011. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 118:3932-3941.
37. Katoh M, Katoh M. 2003. Identification and characterization of ASXL2 gene in silico. Int J Oncol 23:845-850.
38. Katoh M, Katoh M. 2004. Identification and characterization of ASXL3 gene in silico. Int J Oncol 24:1617-1622.
39. Katoh M. 2013. Functional and cancer genomics of ASXL family members. Br J Cancer 109:299-306.
40. Kauffman SL. 1975. Kinetics of pulmonary epithelial proliferation during prenatal growth of the mouse lung. Anat Rec 183:393-403.
41. Kelly TK, De Carvalho DD, Jones PA. 2010. Epigenetic modifications as therapeutic targets. Nat Biotechnol 28:1069-1078.
42. Lai HL, Grachoff M, McGinley AL, Khan FF, Warren CM, Chowdhury SA, Wolska BM, Solaro RJ, Geenen DL, Wang QT. 2012. Maintenance of adult cardiac function requires the chromatin factor Asxl2. J Mol Cell Cardiol 53:734-741.
43. Lai HL, Wang QT. 2013. Additional sex combs-like 2 is required for polycomb repressive complex 2 binding at select targets. PLoS One 8:e73983.
44. Lau C, Rogers JM, Desai M, Ross MG. 2011. Fetal programming of adult disease: implications for prenatal care. Obstet Gynecol 117:978-985.
45. Magini P, Monica MD, Uzielli MLG, Mongelli P, Scarselli G, Gambineri E, Scarano G, Seri M. 2012. Two novel patients with Bohring-Opitz syndrome caused by de novo ASXL1 mutations. Am J Med Genet A 158A:917-921.
46. MacLellan WR, Schneider MD. 2000. Genetic dissection of cardiac growth control pathways. Ann Rev Physiol 62:289-319.
47. Marino B, Digilio MC. 2000. Congenital heart disease and genetic syndromes: specific correlation between cardiac phenotype and genotype. Cardiovasc Pathol 9:303-315.
48. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB. 2006. Contemporary definitions and classification of the cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113:1807-1816.
49. Matarazzo MR, Bonis MLDE, Strazzullo M, Cerase A, Ferraro M, Vastarelli P, Ballestar E, Esteller M, Kudo S, Esposito MD. 2007. Multiple binding of methyl-CpG and polycomb proteins in long-term gene silencing events. J Cell Physiol 719:711-719.
50. McCulley DJ, Black BL. 2012. Transcription factor pathways and congenital heart disease. Curr Top Dev Biol 100:253-277.
51. Minette MS, Sahn DJ. 2006. Ventricular septal defects. Circulation 114:2190-2197.
52. Mitchell ME, Sander TL, Klinkner DB, Tomita-Mitchell A. 2007. The molecular basis of congenital heart disease. Semin Thorac Cardiovasc Surg 19:228-237.
53. Nebbioso A, Carafa V, Benedetti R, Altucci L. 2012. Trials with "epigenetic" drugs: an update. Mol Oncol 6: 657-682.
54. Nemer M. 2008. Genetic insights into normal and abnormal heart development. Cardiovasc Pathol 17:48-54.
55. Ordovás JM, Smith CE. 2010. Epigenetics and cardiovascular disease. Nat Rev Cardiol 7:510-519.
56. Øyen N, Poulsen G, Boyd HA, Wohlfahrt J, Jensen PK, Melbye M. 2009. Recurrence of congenital heart defects in families. Circulation 120:295-301.
57. Piette D, Hendrickx M, Willems E, Kemp CR, Leyns L. 2008. An optimized procedure for whole-mount in situ hybridization on mouse embryos and embryoid bodies. Nat Protoc 3:1194-1201.
58. Pu WT. 2009. Identification of a cardiac disease modifier gene using forward genetics in the mouse. PLoS Genet 5:e1000643.
59. Rajagopal SK, Ma Q, Obler D, Shen J, Manichaikul A, Tomita-Mitchell A, Boardman K, Briggs C, Garg V, Srivastava D, Goldmuntz E, Broman KW, Benson DW, Smoot LB, Pu WT. 2007. Spectrum of heart disease associated with murine and human GATA4 mutation. J Mol Cell Cardiol 43:677-685.
60. Ramirez MI, Millien G, Hinds A, Cao Y, Seldin DC, Williams MC. 2003. T1α, a lung type I cell differentiation gene, is required for normal lung cell proliferation and alveolus formation at birth. Dev Biol 256:62-73.
61. Richards AA, Garg V. 2010. Genetics of congenital heart disease. Curr Cardiol Rev 6:91-97.
62. Sakata Y, Koibuchi N, Xiang F, Youngblood JM, Kamei CN, Chin MT. 2006. The spectrum of cardiovascular anomalies in CHF1/Hey2 deficient mice reveals roles in endocardial cushion, myocardial and vascular maturation. J Mol Cell Cardiol 40:267-273.
63. Salic A, Mitchison TJ. 2008. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci U S A 105:2415-2420.
64. Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, Wilm M, Muir TW, Müller J. 2010. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 465:243-247.
65. Shieh JTC, Srivastava D. 2009. Heart malformation: what are the chances it could happen again? Circulation 120:269-271.
66. Stoller JZ, Demauro SB, Dagle JM, Reese J. 2012. Current perspectives on pathobiology of the ductus arteriosus. J Clin Exp Cardiolog 8:1-29.
67. Toyoda M, Shirato H, Nakajima K, Kojima M, Takahashi M, Kubota M, Suzuki-Migishima R, Motegi Y, Yokoyama M, Takeuchi T. 2003. Jumonji downregulates cardiac cell proliferation by repressing cyclin D1 expression. Dev Cell 5:85-97.
68. Turgeon B, Meloche S. 2009. Interpreting neonatal lethal phenotypes in mouse mutants: Insights into gene function and human diseases. Physiol Rev 89:1-26.
69. Vallaster M, Vallaster CD, Wu SM. 2012. Epigenetic mechanisms in cardiac development and disease. Acta Biochim Biophys Sin (Shanghai) 44:92-102.
70. Van Speybroeck L. 2002. From epigenesis to epigenetics: the case of C. H. Waddington. Ann N Y Acad Sci 981:61-81.
71. van der Bom T, Bouma BJ, Meijboom FJ, Zwinderman AH, Mulder BJM. 2012. The prevalence of adult congenital heart disease, results from a systematic review and evidence based calculation. Am Heart J 164:568-575.
72. Van Weerd JH, Koshiba-Takeuchi K, Kwon C, Takeuchi JK. 2011. Epigenetic factors and cardiac development. Cardiovasc Res 91:203-211.
73. Wang J, Li Z, He Y, Pan F, Chen S, Rhodes S, Nguyen L, Yuan J, Jiang L, Yang X, Weeks O, Liu Z, Zhou J, Ni H, Cai CL, Xu M, Yang FC. 2014. Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. Blood 123:541-553.
74. Wang QT. 2012. Epigenetic regulation of cardiac development and function by polycomb group and trithorax group proteins. Dev Dyn 241:1021-1033.
75. Warburton D, Schwarz M, Tefft D, Flores-Delgado G, Anderson KD, Cardoso WV. 2000. The molecular basis of lung morphogenesis. Mech Dev 92:55-81.
76. Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA, del Nido P, Fasules JW, Graham TP Jr, Hijazi ZM, Hunt SA, King ME, Landzberg MJ, Miner PD, Radford MJ, Walsh EP, Webb GD. 2008. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults with Congenital Heart Disease). J Am Coll Cardiol 52:e143-263.
77. Webb S, Brown NA, Anderson RH. 1998. Formation of the atrioventricular septal structures in the normal mouse. Circ Res 82:645-656.
78. Wheeler FC, Tang H, Marks OA, Hadnott TN, Chu PL, Mao L, Rockman HA, Marchuk DA. 2009. Tnni3k modifies disease progression in murine models of cardiomyopathy. PLoS Genet 5:e1000647.
79. Winston JB, Erlich JM, Green CA, Aluko A, Kaiser KA, Takematsu M, Barlow RS, Sureka AO, LaPage MJ, Janss LL, Jay PY. 2010. Heterogeneity of genetic modifiers ensures normal cardiac development. Circulation 121:1313-1321.
80. Xu K, Nieuwenhuis E, Cohen BL, Wang W, Canty AJ, Danska JS, Coultas L, Rossant J, Wu MYJ, Piscione TD, Nagy A, Gossler A, Hicks GG, Hui CC, Henkelman RM, Yu LX, Sled JG, Gridley T, Egan SE. 2010. Lunatic Fringe-mediated Notch signaling is required for lung alveogenesis. Am J Physiol Lung Cell Mol Physiol 298:45-56.
81. Yokoyama U, Minamisawa S, Quan H, Ghatak S, Akaike T, Segi-Nishida E, Iwasaki S, Iwamoto M, Misra S, Tamura K, Hori H, Yokota S, Toole BP, Sugimoto Y, Ishikawa Y. 2006. Chronic activation of the prostaglandin receptor EP4 promotes hyaluronan-mediated neointimal formation in the ductus arteriosus. J Clin Invest 116:3026-3034.
82. Zhang M, Chen M, Kim JR, Zhou J, Jones RE, Tune JD, Kassab GS, Metzger D, Ahlfeld S, Conway SJ, Herring BP. 2011. SWI/SNF complexes containing Brahma or Brahma-related gene 1 play distinct roles in smooth muscle development. Mol Cell Biol 31:2618-2631.
83. Zhou L, Lim L, Costa RH, Whitsett JA. 1996. Thyroid transcription factor-1, hepatocyte nuclear factor-3beta, surfactant protein B, C, and Clara cell secretory protein in developing mouse lung. J Histochem Cytochem 44:1183-1193.
84. Zhou Y, Kim J, Yuan X, Braun T. 2011. Epigenetic modifications of stem cells: A paradigm for the control of cardiac progenitor cells. Circ Res 109:1067-1081.